VBIV: Gunggung utang perusahaan VBI Vaccines Inc

The price chart on the GURU.Markets platform demonstrates a specific debt level of 0.00. VBI Vaccines Inc. (VBIV) produces an advanced hepatitis B drug, which enables the company to command a premium price in government contracts. The business relies on unique viral structure mimicry to combat brain cancer and infections. Meanwhile, tacit preferences for insurance companies are being utilized to expand the PreHevbrio market.

VBIV: Utang perusahaan VBI Vaccines, Inc. 04.07.2022 - 17.08.2024

VBI Vaccines Inc. (VBIV) - rincian metrik lan laporan keuangan

- rega saham lan konsensus proyeksi valuasi:

Bagan owah-owahan rega vbivaccines.com|VBIV - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Kapitalisasi pasar VBI Vaccines Inc|VBIV - Nilai Total Perusahaan

- data ekuitas miturut neraca:

Nilai Akuntansi Saham VBI Vaccines|VBIV - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Aset Bersih vbivaccines.com|VBIV - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Total Utang marang Modal VBI Vaccines Inc.|VBIV - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal vbivaccines.com|VBIV - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku VBI Vaccines Inc|VBIV - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak VBI Vaccines|Rasio jangkoan perantara vbivaccines.com

- informasi bathi lan kelipatan valuasi:

VBIV - Penghasilan resik

Ringkesan analitik perusahaan:VBI Vaccines, Inc. VBIV

Developing vaccines based on the VLP platform requires significant capital expenditures in biosafety and raw materials to combat glioblastoma and hepatitis B. The dynamics of the total debt load reflect the sum of loans and liabilities to suppliers, allowing investors to assess interest expense risk and the issuer's solvency through daily monitoring of borrowed capital on the VBI Vaccines Inc. (VBIV) chart.

Perusahaan pesaing